Paper Details

  1. Home
  2. Paper Details

Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia.

Author: AittokallioTero, ArribasAlberto J, AthanasiadisPaschalis, BertoniFrancesco, BrownJennifer R, FernandesStacey M, HilliAbdul K, KarlsenLinda, MatoAnthony R, MuraliIshwarya, NormantEmmanuel, SkånlandSigrid S, TaskénKjetil, TjønnfjordGeir E, UrbanAleksandra, XuHaifeng, YinYanping

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

PI3Ki are used to treat relapsed CLL but often have side effects and resistance. This study aimed to identify actionable biomarkers to predict individual treatment responses and overcome these challenges.
Paper Details　
Original Abstract of the Article :
PI3K inhibitors (PI3Ki) are approved for relapsed chronic lymphocytic leukemia (CLL). Although patients may show an initial response to these therapies, development of treatment intolerance or resistance remain clinical challenges. To overcome these, prediction of individual treatment responses base...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/35998013

データ提供：米国国立医学図書館（NLM）

Functional Testing: A Potential Tool to Personalize PI3K Inhibitor Therapy

This research investigates the use of functional testing to predict the response of chronic lymphocytic leukemia (CLL) patients to PI3K inhibitors (PI3Ki). The study explored the activity and cellular effects of various PI3Ki and assessed whether functional analysis could identify treatment vulnerabilities in PI3Ki-refractory/intolerant CLL. The researchers found that functional analysis can potentially identify treatment vulnerabilities in PI3Ki-refractory/intolerant CLL and stratify responders to PI3Ki.

Predicting Treatment Response with Functional Testing

The study's findings suggest that functional testing can be a valuable tool for predicting treatment response to PI3Ki in CLL. This information could help clinicians personalize treatment strategies, maximizing the effectiveness of PI3Ki therapy and minimizing the risk of resistance or intolerance.

Toward More Personalized Cancer Treatment

This research represents a step towards more personalized cancer treatment, tailoring therapy to the specific needs of each patient. Just as a desert traveler chooses their path based on the terrain, personalized treatment strategies empower clinicians to navigate the complexities of cancer treatment and optimize patient outcomes.

Dr. Camel's Conclusion

This study underscores the importance of functional testing in predicting treatment response to PI3K inhibitors in CLL. The potential to personalize treatment strategies based on functional testing could lead to more effective and targeted therapies for patients with CLL. This research is a reminder that the desert of cancer research is constantly evolving, with new tools and approaches emerging to improve patient care.

Date :
  1. Date Completed 2022-10-17
  2. Date Revised 2023-09-18
Further Info :

Pubmed ID

35998013

DOI: Digital Object Identifier

NIHMS1833298

Related Literature

Article Analysis
・Effects of idelalisib・Effects of umbralisib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.